Apixaban to Prevent Recurrence After Cryptogenic Stroke—Reply
JAMA · 11.06.2024 · 331 (22) · 1966
DOI: 10.1001/jama.2024.6855 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, erschienen am 11.06.2024. Verfasst von Hooman Kamel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Atrial Fibrillation, Factor Xa Inhibitors, Ischemic Stroke, Pyrazoles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 1 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Weill Cornell Medicine, New York, New York.
- Department of Neurology, University of Washington, Seattle.
- Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Zitieren
APA
Kamel, H., Tirschwell, D. L., Elkind, M. S. V., & ARCADIA Investigators (2024). Apixaban to Prevent Recurrence After Cryptogenic Stroke—Reply. JAMA, 331(22), 1966. https://doi.org/10.1001/jama.2024.6855
Vancouver
Kamel H, Tirschwell DL, Elkind MSV, ARCADIA Investigators. Apixaban to Prevent Recurrence After Cryptogenic Stroke—Reply. JAMA. 2024;331(22):1966. doi:10.1001/jama.2024.6855
BibTeX
@article{Kamel2024,
author = {Kamel, Hooman and Tirschwell, David L and Elkind, Mitchell S V and ARCADIA Investigators, ARCADIA Investigators},
title = {Apixaban to Prevent Recurrence After Cryptogenic Stroke—Reply},
journal = {JAMA},
year = {2024},
volume = {331},
number = {22},
pages = {1966},
doi = {10.1001/jama.2024.6855}
}
EUVIMED